Virginia Retirement Systems Et Al Immunovant, Inc. Transaction History

Virginia Retirement Systems Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jul 11, 2023	SELL	$15.27 - $19.72 $797,094 - $1.03 Million	-52,200 Reduced 73.31%	19,000 $294,000
Q4 2022 May 17, 2023	SELL	$6.59 - $17.75 $247,784 - $667,400	-37,600 Reduced 34.56%	71,200 $1.26 Billion
Q3 2022 May 16, 2023	BUY	$3.93 - $6.37 $128,118 - $207,662	32,600 Added 42.78%	108,800 $607 Million
Q1 2022 Apr 21, 2022	SELL	$5.06 - $8.77 $12,143 - $21,048	-2,400 Reduced 3.05%	76,200 $420,000
Q4 2021 Feb 03, 2022	BUY	$7.33 - $9.32 $33,718 - $42,872	4,600 Added 6.22%	78,600 $670,000
Q3 2021 Oct 21, 2021	BUY	$7.01 - $11.37 $353,304 - $573,048	50,400 Added 213.56%	74,000 $643,000
Q2 2021 Aug 13, 2021	SELL	$9.4 - $16.85 $31,020 - $55,605	-3,300 Reduced 12.27%	23,600 $249,000
Q1 2021 Apr 30, 2021	SELL	$13.08 - $49.6 $65,400 - $248,000	-5,000 Reduced 15.67%	26,900 $431,000
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $818,100 - $1.19 Million	22,500 Added 239.36%	31,900 $1.47 Million
Q3 2020 Nov 12, 2020	BUY	$22.61 - $38.9 $212,534 - $365,660	9,400 New	9,400 $331,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

Stay updated on Virginia Retirement Systems Et Al with notifications on news.